A phase I trial of the oral cyclin dependent kinase inhibitor CYC202 in patients with advanced malignancy

被引：0

作者：

White, JD

Cassidy, J

Twelves, C

Benson, C

Pacey, S

Judson, I

McGrath, H

Rose, F

Frenz, L

机构：

[1] Western Infirm & Associated Hosp, Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland

[2] Royal Marsden Hosp, RMH, Sutton, Surrey, England

[3] Canc Res UK, London, England

[4] Cyclacel Ltd, Dundee, Scotland

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3042

引用

页码：205S / 205S

页数：1

共 50 条

[31] Phase 1 safety, pharmacokinetic and pharmacodynamic study of fadraciclib (CYC065), a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953)
Do, K. T.
Frej, K.
Bhushan, K.
Pruitt-Thompson, S.
Zheleva, D.
Blake, D.
Chiao, J.
Shapiro, G. I.
EUROPEAN JOURNAL OF CANCER, 2020, 138 : S7 - S7
[32] Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma
Raje, N
Kumar, S
Hideshima, T
Roccaro, A
Ishitsuka, K
Yasui, H
Shiraishi, N
Chauhan, D
Munshi, NC
Green, SR
Anderson, KC
BLOOD, 2005, 106 (03) : 1042 - 1047
[33] Phase I trial of imexon in patients with advanced malignancy
Dragovich, Tomislav
Gordon, Michael
Mendelson, David
Wong, Lucas
Modiano, Manuel
Chow, H. H. Sherry
Samulitis, Betty
O'Day, Steven
Grenier, Kathryn
Hersh, Evan
Dorr, Robert
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1779 - 1784
[34] Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Flaherty, Keith T.
LoRusso, Patricia M.
DeMichele, Angela
Abramson, Vandana G.
Courtney, Rachel
Randolph, Sophia S.
Shaik, M. Naveed
Wilner, Keith D.
O'Dwyer, Peter J.
Schwartz, Gary K.
CLINICAL CANCER RESEARCH, 2012, 18 (02) : 568 - 576
[35] A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol
Dickson, Mark A.
Shah, Manish A.
Rathkopf, Dana
Tse, Archie
Carvajal, Richard D.
Wu, Nian
Lefkowitz, Robert A.
Gonen, Mithat
Cane, Lauren M.
Dials, Heather J.
Schwartz, Gary K.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) : 1113 - 1121
[36] A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol
Mark A. Dickson
Manish A. Shah
Dana Rathkopf
Archie Tse
Richard D. Carvajal
Nian Wu
Robert A. Lefkowitz
Mithat Gonen
Lauren M. Cane
Heather J. Dials
Gary K. Schwartz
Cancer Chemotherapy and Pharmacology, 2010, 66 : 1113 - 1121
[37] A phase I study of R547, a novel cyclin dependent kinase inhibitor, in patients (pts) with advanced cancer: preliminary results
Camidge, D. R.
Eckhardt, S. G.
Tan, A.
Frenette, G.
Diab, S.
Depinto, W.
Grippo, J. F.
DeMario, M.
Mikulski, S.
Papadimitrakopoulou, V.
EJC SUPPLEMENTS, 2006, 4 (12): : 89 - 89
[38] Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients
Tamura, Kenji
Mukai, Hirofumi
Naito, Yoichi
Yonemori, Kan
Kodaira, Makoto
Tanabe, Yuko
Yamamoto, Noboru
Osera, Shozo
Sasaki, Masaoki
Mori, Yuko
Hashigaki, Satoshi
Nagasawa, Takashi
Umeyama, Yoshiko
Yoshino, Takayuki
CANCER SCIENCE, 2016, 107 (06) : 755 - 763
[39] Phase I study of seliciclib (CYC202 or R-roscovitine) in combination with gemcitabine (gem)/cisplatin (cis) in patients with advanced non-small cell lung cancer (NSCLC).
Siegel-Lakhai, WS
Rodenstein, DO
Beijnen, JH
Gianella-Borradori, A
Schellens, JHM
Talbot, DC
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 150S - 150S
[40] Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma
Schwartz, GK
Ilson, D
Saltz, L
O'Reilly, E
Tong, W
Maslak, P
Werner, J
Perkins, P
Stoltz, M
Kelsen, D
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (07) : 1985 - 1992

← 1 2 3 4 5 →